Summary
Definition
History and exam
Key diagnostic factors
- recent history of immersion in spa water
- new medication commenced known to be associated with folliculitis
Other diagnostic factors
- recent history of shaving
- umbilicated, flesh-coloured papules
- papules on one side of the face in the submaxillary area
- small, uniform papules and pustules
- background erythema
- alopecia/scalp scaling
- erythematous plaques with haemorrhagic crusts in a dermatomal distribution
Risk factors
- trauma, including shaving and extraction
- topical corticosteroid preparations
- diabetes mellitus
- immunosuppression
- occlusion and perspiration
- systemic antibiotics
- immersion in under-chlorinated water
- drugs
Diagnostic investigations
Investigations to consider
- bacterial skin swab
- viral skin swab
- skin scraping for mycology
- tissue culture
- skin biopsy
Treatment algorithm
Contributors
Authors
Joshua Hekmatjah, BS
Clinical Research Fellow
Dermatology Department
Keck School of Medicine of USC
University of Southern California
Los Angeles
CA
Disclosures
JH declares that he has no competing interests.
Nazanin Ehsani-Chimeh, MD
Clinical Research Fellow
Dermatology Department
Keck School of Medicine of USC
University of Southern California
Los Angeles
CA
Disclosures
NEC declares that she has no competing interests.
April W. Armstrong, MD, MPH
Associate Dean, Clinical Research
Associate Professor of Dermatology
Keck School of Medicine of USC
University of Southern California
Los Angeles
CA
Disclosures
AWA has served as an investigator for Abbvie, Bristol-Myers-Squibb, Dermavent, Janssen, Eli Lilly, Modernizing Medicine, Novartis, OrthoDermalogics, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, and Sun Pharma; has been a speaker for Abbvie, Regeneron, and Sanofi Genzyme; and is a member of the data safety monitoring board for Boehringer Ingelheim/Paraxel. Her institution has received funding from Bristol-Myers-Squibb, Dermavent, Dermira, Eli Lilly, Galderma, Janssen-Ortho, Kyowa Hakko Kirin, Leo Pharma, Pfizer, and UCB Pharma.
Acknowledgements
Joshua Hekmatjah, Dr Nazanin Ehsani-Chimeh, and Dr April W. Armstrong would like to gratefully acknowledge Professor Howard Baden, a previous contributor to this topic.
Disclosures
HB declares that he has no competing interests.
Peer reviewers
Lowell Goldsmith, MD
Professor of Dermatology
Dean Emeritus
School of Medicine and Dentistry
University of North Carolina
Chapel Hill
NC
Disclosures
LG is editor-in-chief and co-founder of Logicalimages, Inc, which has print and electronic products for education and point-of-care; he has stock and stock options in that corporation. He is on the clinical and scientific advisory boards of Anacor Inc, which is developing anti-inflammatory and anti-infective products that are in early clinical trials; he receives payments and stock options for those services.
Dedee F. Murrell, MA, BMBCh, FAAD, MD
Head of Department
Department of Dermatology
St George Hospital
Conjoint Professor
University of New South Wales
Sydney
Australia
Disclosures
DFM declares that she has no competing interests.
Use of this content is subject to our disclaimer